What is Novelstem Intl Corp's earnings per share (EPS)?

Novelstem Intl Corp (NSTM) reported diluted earnings per share of $0.05 for fiscal year 2025. This represents a 171.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Novelstem Intl Corp Financials

NSTM

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Novelstem Intl Corp (NSTM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NSTM FY2025 2026-05-15

Shrinking assets and financing support show a business surviving through balance-sheet contraction rather than self-funded operations.

In two years, total assets fell from $2.25M to $15.8K while equity stayed negative, which means the company’s financial structure weakened far faster than a simple loss figure would suggest. That makes the drop in interest expense to $36K look more like a lighter burden on a much smaller balance sheet than evidence that the core business is now generating its own support.

Across the last two reported cash-flow years, the operating side consumed cash, while financing inflows of $645K and $475K supplied funds that operations did not. Because year-end cash still shrank to just $333, those inflows functioned more like temporary support than a stable liquidity base.

Short-term flexibility deteriorated sharply: the current ratio fell to 0.006x, and latest cash on hand was only $333. That combination points to a business constrained first by near-term liquidity, not merely by weak accounting earnings.

Financial Health Signals

Financial Profile 16/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Novelstem Intl Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Novelstem Intl Corp carries a low D/E ratio of -1.01, meaning only $-1.01 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$0.05

YoY+171.4%

Novelstem Intl Corp earned $0.05 per diluted share (EPS) in fiscal year 2025. This represents an increase of 171.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$333

YoY-94.5%

5Y CAGR-87.6%

Novelstem Intl Corp held $333 in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

47M

YoY+0.0%

5Y CAGR+15.1%

Novelstem Intl Corp had 47M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

NSTM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY12
Revenue	N/A	N/A	N/A	N/A	N/A	$616K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	$665K-10.6%	$744K+50.2%	$496K-82.6%	$2.9M
Operating Income	N/A	N/A	-$3.5M-734.6%	-$422K+14.8%	-$496K+91.3%	-$5.7M
Interest Expense	$36K-91.5%	$425K+329.6%	$99K+798.7%	$11K+61.4%	$7K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	-$5.8M
Net Income	N/A	N/A	-$4.2M-446.8%	-$766K+43.1%	-$1.3M-112.9%	$10.4M
EPS (Diluted)	$0.05+171.4%	$-0.07+22.2%	$-0.09-350.0%	$-0.02	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$5K	N/A	$39K-38.3%	$64K-32.4%	$95K	N/A	$567K+293.4%	$144K
Operating Income	-$5K	N/A	-$39K+38.3%	-$64K+32.4%	-$95K	N/A	-$564K-299.6%	-$141K
Interest Expense	$36K	N/A	$44K+21.4%	$36K-68.0%	$113K	N/A	$105K-1.2%	$107K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$55K	N/A	N/A	N/A	-$207K	N/A	N/A	-$303K
EPS (Diluted)	$0.00	N/A	N/A	$0.06	$0.00	N/A	$-0.05-400.0%	$-0.01

NSTM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY12
Total Assets	$16K-90.1%	$160K-92.9%	$2.3M-1.4%	$2.3M-12.4%	$2.6M-90.2%	$26.6M
Current Assets	$16K-50.5%	$32K-63.2%	$87K+47.0%	$59K+59.3%	$37K-99.7%	$13.6M
Cash & Equivalents	$333-94.5%	$6K-88.5%	$53K+736.2%	$6K-26.8%	$9K-99.9%	$11.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$11K	N/A	$12K	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	$6.2M
Total Liabilities	$2.2M-59.3%	$5.3M+26.1%	$4.2M+1090.4%	$353K+82.9%	$193K-88.3%	$1.7M
Current Liabilities	N/A	$5.3M+1431.0%	$346K+434.1%	$65K-66.4%	$193K-87.8%	$1.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.1M+58.4%	-$5.1M-163.6%	-$2.0M-201.0%	$1.9M-20.0%	$2.4M-90.3%	$25.0M
Retained Earnings	-$294.0M+0.8%	-$296.4M-1.1%	-$293.1M-1.4%	-$288.9M-0.3%	-$288.2M-7.2%	-$268.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$101K+539.2%	$16K+6.3%	$15K-2.9%	$15K-89.8%	$150K-6.3%	$160K-19.3%	$198K-91.5%	$2.3M
Current Assets	$101K+539.2%	$16K+6.3%	$15K-2.9%	$15K-29.7%	$22K-31.8%	$32K-53.8%	$69K+139.7%	$29K
Cash & Equivalents	$90K+26882.0%	$333-46.9%	$627-43.3%	$1K-67.5%	$3K-44.2%	$6K-86.5%	$45K+475.8%	$8K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$11K+40.0%	$8K+66.7%	$5K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.0M-5.1%	$2.2M+4.4%	$2.1M+3.9%	$2.0M-63.8%	$5.5M+3.6%	$5.3M+2.2%	$5.2M+6.5%	$4.9M
Current Liabilities	N/A	N/A	N/A	N/A	N/A	$5.3M+47.4%	$3.6M+2.4%	$3.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.9M+9.1%	-$2.1M-4.4%	-$2.1M-3.9%	-$2.0M+63.0%	-$5.3M-3.9%	-$5.1M-3.1%	-$5.0M-96.8%	-$2.5M
Retained Earnings	-$294.0M0.0%	-$294.0M0.0%	-$293.9M0.0%	-$293.8M+0.9%	-$296.6M-0.1%	-$296.4M-0.1%	-$296.2M-0.8%	-$293.7M

NSTM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY12
Operating Cash Flow	N/A	-$272K+21.9%	-$348K-91.0%	-$182K-0.8%	-$181K+95.4%	-$3.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$84K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$4.0M
Investing Cash Flow	N/A	-$250K0.0%	-$250K	N/A	N/A	$11.7M
Financing Cash Flow	N/A	$475K-26.4%	$645K+258.3%	$180K+80.0%	$100K+314.1%	-$47K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$139K-429.9%	-$26K+15.4%	-$31K+53.7%	-$67K-52.9%	-$44K-11.4%	-$39K+37.3%	-$63K+35.7%	-$97K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Financing Cash Flow	$228K+781.7%	$26K-15.1%	$30K-52.7%	$65K+57.3%	$41K	$0-100.0%	$100K0.0%	$100K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NSTM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY12
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	-925.2%
Net Margin	N/A	N/A	N/A	N/A	N/A	1688.9%
Return on Equity	N/A	N/A	N/A	-39.6%+16.1pp	-55.7%-97.4pp	41.7%
Return on Assets	N/A	N/A	-185.7%-152.2pp	-33.5%+18.1pp	-51.6%-90.7pp	39.1%
Current Ratio	N/A	0.01-0.2	0.25-0.7	0.91+0.7	0.19-8.4	8.63
Debt-to-Equity	-1.01+0.0	-1.03+1.1	-2.16-2.3	0.18+0.1	0.08+0.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	-649.0%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-54.5%	N/A	N/A	N/A	-138.2%	N/A	N/A	-12.9%
Current Ratio	N/A	N/A	N/A	N/A	N/A	0.01-0.0	0.02+0.0	0.01
Debt-to-Equity	-1.05-0.0	-1.010.0	-1.010.0	-1.01+0.0	-1.030.0	-1.030.0	-1.04+0.9	-1.92
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$2.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Identa Ltd Rvice IDTA

$647K

Justera Health Ltd SCRSF

$496K

Invitro Internat IVRO

$1.7M

Cardiogenics CGNH

$1.9M

Rushnet Inc RSHN

$429K

Frequently Asked Questions

What are Novelstem Intl Corp's total assets?

Novelstem Intl Corp (NSTM) had $16K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Novelstem Intl Corp have outstanding?

Novelstem Intl Corp (NSTM) had 47M shares outstanding as of fiscal year 2025.

What is Novelstem Intl Corp's debt-to-equity ratio?

Novelstem Intl Corp (NSTM) had a debt-to-equity ratio of -1.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Novelstem Intl Corp's debt-to-equity ratio negative or unusual?

Novelstem Intl Corp (NSTM) has negative shareholder equity of -$2.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Novelstem Intl Corp?

Novelstem Intl Corp (NSTM) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.